Allergic Rhinitis. Other allergic rhinitis
Conditions
Interventions
Intervention 1: Intervention group: The patients were treated with urtica dioica (150 mg qid for one month. Intervention 2: Control group:The patients were treated with placebo for one month.
Treatment - Drugs
Placebo
Intervention group: The patients were treated with urtica dioica (150 mg qid for one month
Control group:The patients were treated with placebo for one month.
Sponsors
Vice Chancellor for Research, Mashhad University of Medical Science
Eligibility
Sex/Gender
All
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Clinical and laboratory diagnosis perennial allergic rhinitis; Patients' willingness to participate in treatment and plan Exclusion criteria: The risk of other causes of rhinitis; Systemic diseases such as polycythemia; Use of other drugs with anti-inflammatory properties;Use of any herbal remedy; Intolerance of side effects urtica dioica; Drug use weak immune system; Use of antidiabetic drugs; Use of hypertensive drugs; Pregnancy & Breastfeeding; Age less than 15 years and more than 45 years.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms of Allergic rhinitis. Timepoint: Befor and after treatment. Method of measurement: SNOT - 22. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood level of IgE. Timepoint: Before and after treatment. Method of measurement: ELISA.;Blood level of IL5. Timepoint: Before and after treatment. Method of measurement: ELISA.;Blood level of IL4. Timepoint: Before and after treatment. Method of measurement: ELISA.;Blood level of INF Gamma. Timepoint: Before and after treatment. Method of measurement: ELISA.;Nasal eosinophil count. Timepoint: Before and after treatment. Method of measurement: Eosinophil count. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Bakhshaee
Mashhad university of Medical Science
Outcome results
None listed